News & Updates
Filter by Specialty:
Methylnaltrexone proves safety in paediatric oncology patients with constipation
Subcutaneous methylnaltrexone is safe to use in children with cancer who have opioid-induced constipation, suggest the results of a study. In addition, this agent stimulates bowel movements in more than a third of paediatric patients.
Methylnaltrexone proves safety in paediatric oncology patients with constipation
24 Feb 2024
Children of mothers with AD prone to develop AD, other allergic illness
Children whose mothers have atopic dermatitis (AD) are likely to develop the same disease, while some develop other allergic illness (OAI) first, reports a study. This suggests that not everyone will follow the same sequential pathway.
Children of mothers with AD prone to develop AD, other allergic illness
22 Feb 2024
Infliximab, vedolizumab similarly effective as 1L Tx for paediatric IBD
In a study presented at Crohn’s and Colitis Congress 2024, infliximab and vedolizumab were found to have similar effectiveness in achievÂing steroid-free clinical remission (SFCR) and biochemical remission (BR) at 12 months when used as first-line treatment for biologic-naïve paediatric patients with unÂcomplicated mild-to-moderately active inflammatory bowel disease (IBD).
Infliximab, vedolizumab similarly effective as 1L Tx for paediatric IBD
22 Feb 2024
Cardiogenic shock ups risk of death in hospitalized children with ADHF
Nearly one in four children hospitalized for acute decompensated heart failure (ADHF) had cardiogenic shock (CS), which may lead to death, reports a study.